Matinas BioPharma Holdings, Inc.

MTNB

US5768101058

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.1818 ^USD	+0.17%		-5.31%	-15.91%

Mar. 27	Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024
Mar. 27	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Matinas BioPharma Holdings, Inc. Elects Kathryn Corzo to the Board of Directors

November 01, 2021 at 05:15 pm EDT

Matinas BioPharma Holdings, Inc. announced at annual general meeting held on November 1, 2021, the shareholders elected Kathryn Corzo to the board of directors of the company.

Latest news about Matinas BioPharma Holdings, Inc.

Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024	Mar. 27
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation	Mar. 25	CI
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	Feb. 26	CI
Matinas Reaches Agreement With FDA For Late-Stage Invasive Aspergillosis Trial	Feb. 20	MT
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis	Feb. 20	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Dec. 27	MT
Matinas BioPharma Shares Rise After Studies Show Successful Oral Delivery of Genetic Material Using its Technology	Dec. 27	MT
Sector Update: Health Care	Dec. 27	MT
Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides	Dec. 27	CI
Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA	Dec. 21	CI
Transcript : Matinas BioPharma Holdings, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model	Nov. 07	CI
US Equity Markets Close Higher Wednesday Despite Stronger-Than-Expected Wholesale Prices	23-10-11	MT
Top Midday Gainers	23-10-11	MT
Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient?s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203	23-10-11	CI
Matinas BioPharma Holdings, Inc.(NYSEAM:MTNB) dropped from S&P Global BMI Index	23-09-18	CI
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases	23-08-22	CI
Transcript : Matinas BioPharma Holdings, Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Transcript : Matinas BioPharma Holdings, Inc., Q1 2023 Earnings Call, May 10, 2023	23-05-10
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI

Chart Matinas BioPharma Holdings, Inc.

Duration

Period

More charts

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFÎ±.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1818 USD

Average target price

1 USD

Spread / Average Target

+450.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MATINAS BIOPHARMA HOLDINGS, INC.	-15.91%	45.6M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs